PCSK9 inhibitors safely and effectively lower LDL after heart transplantation: a systematic review and meta-analysis

[1]  A. Magalski,et al.  PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. , 2021, Journal of cardiac failure.

[2]  M. Guglin,et al.  Utilization of PCSK-9 Inhibitors in Statin Intolerant Cardiac Transplant Patients , 2020 .

[3]  E. Mayo-Wilson,et al.  The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2020, BMJ.

[4]  G. Dellgren,et al.  Cholesterol lowering with EVOLocumab to prevent cardiac allograft Vasculopathy in De‐novo heart transplant recipients: Design of the randomized controlled EVOLVD trial , 2020, Clinical transplantation.

[5]  R. Cole,et al.  PCSK9 inhibition in patients with heart transplantation: A case series. , 2019, Journal of clinical lipidology.

[6]  M. Crespo-Leiro,et al.  Treatment of hypercholesterolemia with PCSK9 inhibitors in heart transplant recipients. First experience in Spain. , 2019, Revista espanola de cardiologia.

[7]  R. Dhingra,et al.  Immunologic Response to PCSK9 Inhibitors in Orthotopic Heart Transplant Recipients: A Case Series , 2019, Journal of Cardiac Failure.

[8]  G. Laufer,et al.  Treatment of Therapy-Resistant Hyperlipidaemia after Heart Transplant with PCSK9-Inhibitors , 2019, The Journal of Heart and Lung Transplantation.

[9]  G. Hindricks,et al.  Treatment of hypercholesterolaemia with PCSK9 inhibitors in patients after cardiac transplantation , 2019, PloS one.

[10]  J. Knowles,et al.  Safety and Efficacy of PCSK9 Inhibitors After Heart Transplantation. , 2019, The Canadian journal of cardiology.

[11]  M. Shullo,et al.  Optimal low‐density lipoprotein concentration for cardiac allograft vasculopathy prevention , 2018, Clinical transplantation.

[12]  B. Rangan,et al.  Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials , 2017, Journal of the American Heart Association.

[13]  A. Vallakati,et al.  Impact of Statin Use After Heart Transplantation: A Meta-Analysis , 2016, Circulation. Heart failure.

[14]  Deepak L. Bhatt,et al.  Allograft Vasculopathy: The Achilles' Heel of Heart Transplantation. , 2016, Journal of the American College of Cardiology.

[15]  Jelle J Goeman,et al.  Plea for routinely presenting prediction intervals in meta-analysis , 2016, BMJ Open.

[16]  Jiming Liu,et al.  Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range , 2014, BMC Medical Research Methodology.

[17]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[18]  Clive Lewis,et al.  The International Society of Heart and Lung Transplantation Guidelines for the care of heart transplant recipients. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[19]  Guido Knapp,et al.  Improved tests for a random effects meta‐regression with a single covariate , 2003, Statistics in medicine.

[20]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[21]  J. Cutler,et al.  Variance imputation for overviews of clinical trials with continuous response. , 1992, Journal of clinical epidemiology.

[22]  M. Farr,et al.  PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature. , 2019, Transplantation.